October 3, 2025Clinical ChemistryOpen Access

B-364 Changing Immunochemistry Platforms: Analytical and Clinical analysis of cancer antigen (CA) 15-3 and 27.29 testing

View Full Paper

Ask AI

Bookmark

CA 15-3 values showed a consistent drop of about 30% between two testing platforms, indicating the need for re-baselining.
Trends from proficiency testing showed a shift in preference towards CA 15-3 while CA 27.29 remains complicated by differential results.
Longitudinal assessments confirmed strong correlation in percentage changes between CA 15-3 and CA 27.29 despite systematic value differences.
The transition from CA 27.29 to CA 15-3 reflects wider clinical practice trends, maintaining effective patient monitoring during assay shifts.

Discussion

No takes yet. Share an insight, caveat, or question.

Analytical comparisons reveal distinct results for CA 15-3 and CA 27.29 testing in metastatic breast cancer, suggesting re-baselining is essential.

Usman et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analytical comparisons reveal distinct results for CA 15-3 and CA 27.29 testing in metastatic breast cancer, suggesting re-baselining is essential.